
|Articles|March 3, 2020
Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer
https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
Patients Face New Care Complexities as DTC Options Expand
3
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































